(Corrects name of rare neurological disorder, to ATTRv-PN, in paragraph 9) By Maggie Fick LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company ...
A late-stage gastric-cancer study met its overall-survival goal, supporting AstraZeneca's multibillion-dollar peak-sales estimate.
LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above ...
Analysis-AstraZeneca 'magic' faces rare test after trial failure, share slide FILE PHOTO: AstraZeneca CEO Pascal Soriot attends an announcement about lowering U.S. drug prices, at the White House in ...
LONDON, July 24 (Reuters) - AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results